Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRIDE: Semaglutide in Type 2 Diabetes With Peripheral Arterial Disease
jRCT2031200141Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
01
Overview
Randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and arteriosclerosis obliterans comparing Semaglutide arm with Placebo arm (2 arms). Primary endpoint: Maximum walking distance at week 52. Started Oct 2020; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)arteriosclerosis obliterans
Beyond the preview
Go deeper on jRCT2031200141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200141.